Background: Postherpetic neuralgia (PHN) is a debilitating neuropathic pain condition that persists after herpes zoster infection, often resistant to conventional medications. This study compares the long-term efficacy and safety of short-term spinal cord stimulation (stSCS) versus bipolar pulsed radiofrequency (bPRF) in managing refractory PHN.

Methods: In this prospective, controlled observational study, 140 PHN patients (aged ≥ 18 years; PHN duration ≥ 3 months) with inadequate pain relief from standard therapies were enrolled and randomized equally into two groups (n = 70 each). The stSCS group received percutaneous implantation of an 8-contact electrode for temporary neuromodulation, while the bPRF group underwent application of controlled high-frequency pulses to the dorsal root ganglion. Outcome measures included pain intensity (VAS, NRS), neuropathic pain characteristics (DN4), quality of life (SF-36, EQ-5D), sleep quality (PSQI), and psychological status (SAS, SDS), assessed at baseline and at follow-up intervals over 24 months.

Results: Both stSCS and bPRF achieved significant short-term pain relief. However, from 6 to 24 months post-treatment, the stSCS group demonstrated significantly lower VAS scores and superior pain control compared to the bPRF group. In addition, improvements in sleep quality and emotional well-being were more pronounced in the stSCS group at 12, 18, and 24 months. Both treatments exhibited favorable safety profiles with only minor, transient adverse events reported.

Conclusions: While both stSCS and bPRF effectively alleviate pain in patients with refractory PHN, stSCS offers superior long-term benefits in pain reduction, sleep quality, and psychological outcomes. These findings suggest that stSCS may be the preferred neuromodulation strategy for patients with chronic PHN requiring sustained symptom management.